跳至主要内容
临床试验/NCT02968342
NCT02968342Unknown4 期

Role of Progesterone in Hypoactive Sexual Desire Disorder in Menopausal Women

Bezmialem Vakif University2 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2016年7月最近更新:
适应症
干预措施

试验速览

阶段
4 期
入组人数
30
试验地点
2
主要终点
FSFI (Female Sexual Function Index) questionnaire "arousal" domain

研究概览

简要总结

The objective of this study is the role of vaginal progesterone gel in the treatment of menopausal hypoactive sexual desire disorder. Half of the study participants will receive a standard dose of self applied vaginal progesterone gel and the other half will receive oral vitamin tablets.

详细描述

Steroid hormones play fundamental roles in sexual behaviour. Sexual activity is related to hormone concentrations and ovulation in women. Women's sexuality, unlike that of most mammals, is not solely defined by sexual receptivity during the short window of fertility. Women are also prone to initiate luteal-phase sex when serum levels of progesterone are highest in the menstrual cycle.As a result of ovarian hormonal cessation after menopause women may face alterations in sexual desire.

The role of progesterone supplementation in improving sexual desire in the menopausal period is investigated.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
40 Years 至 80 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Menopausal status
  • Sexually active

排除标准

  • Medical history of chronic psychiatric disease
  • Medical conditions associated with female sexual dysfunction; cardiovascular disease, uncontrolled chronic HT (hypertension) ,DM (diabetes mellitus), History of gynecologic surgery, female gynecological cancer ( breast, ovarian, uterine, cervical)
  • Medications associated with female sexual dysfunction; Antidepressants opiates, beta blockers, Antiepileptics ( gabapentin, topiramate,phenytoin) benzodiazepines

研究组 & 干预措施

Vaginal progesterone 8%

Experimental

Vaginal progesterone application 8%

干预措施: Vaginal progesterone 8% (Device)

Placebo

Placebo Comparator

Oral multivitamin supplement

干预措施: Vaginal progesterone 8% (Device)

结局指标

主要结局

FSFI (Female Sexual Function Index) questionnaire "arousal" domain

时间窗: 1 month

Increment

次要结局

  • FSDS-R (Female Sexual Distress Scale- Revised) score(1 month)
  • FSFI (Female Sexual Function Index) questionnaire "lubrication" domain(1 month)
  • FSFI (Female Sexual Function Index) questionnaire all domains(1 month)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验